JP2016530265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530265A5 JP2016530265A5 JP2016534801A JP2016534801A JP2016530265A5 JP 2016530265 A5 JP2016530265 A5 JP 2016530265A5 JP 2016534801 A JP2016534801 A JP 2016534801A JP 2016534801 A JP2016534801 A JP 2016534801A JP 2016530265 A5 JP2016530265 A5 JP 2016530265A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- methylumbelliferone
- disease
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 47
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 claims description 31
- 210000003289 regulatory T cell Anatomy 0.000 claims description 16
- 208000012657 Atopic disease Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 102000016354 Glucuronosyltransferase Human genes 0.000 claims description 9
- 108010092364 Glucuronosyltransferase Proteins 0.000 claims description 9
- 229940123064 Glycosyl transferase inhibitor Drugs 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000003297 glycosyltransferase inhibitor Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 9
- 229940099552 hyaluronan Drugs 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 230000005867 T cell response Effects 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- ARQXEQLMMNGFDU-JHZZJYKESA-N 4-methylumbelliferone beta-D-glucuronide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ARQXEQLMMNGFDU-JHZZJYKESA-N 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 206010012305 Demyelination Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 30
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865084P | 2013-08-12 | 2013-08-12 | |
| US61/865,084 | 2013-08-12 | ||
| PCT/US2014/050770 WO2015023691A2 (en) | 2013-08-12 | 2014-08-12 | 4-methylumbelliferone treatment for immune modulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019095974A Division JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530265A JP2016530265A (ja) | 2016-09-29 |
| JP2016530265A5 true JP2016530265A5 (enExample) | 2017-09-14 |
Family
ID=52468796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534801A Withdrawn JP2016530265A (ja) | 2013-08-12 | 2014-08-12 | 免疫調節のための４−メチルウンベリフェロン処置 |
| JP2019095974A Pending JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019095974A Pending JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10285976B2 (enExample) |
| EP (1) | EP3033416A4 (enExample) |
| JP (2) | JP2016530265A (enExample) |
| CN (1) | CN105579578A (enExample) |
| WO (1) | WO2015023691A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| JP6952350B2 (ja) * | 2016-06-10 | 2021-10-20 | 国立大学法人東北大学 | インスリン分泌促進剤又はインスリン抵抗性改善剤 |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| US11278518B2 (en) | 2017-01-13 | 2022-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatment using 4-methylumbelliferone and derivatives thereof |
| US10370400B2 (en) * | 2017-01-13 | 2019-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
| WO2019165319A1 (en) * | 2018-02-23 | 2019-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | The use of 4-methylumbelliferone to prevent immune rejection in cases of tissue transplantation |
| US20190321641A1 (en) * | 2018-03-29 | 2019-10-24 | Nevro Corp. | Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods |
| CA3123089A1 (en) * | 2018-12-20 | 2020-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Hyaluronan synthesis inhibition for treating autoimmune, inflammatory, fibrotic, or proliferative diseases or disorders |
| EP4048257A1 (en) * | 2019-10-25 | 2022-08-31 | Jessica Kwok | Treatment of conditions of the nervous system |
| WO2021203051A1 (en) * | 2020-04-03 | 2021-10-07 | Standard Of Care Corporation | Aerosolized hyaluronidase and/or 4-methylumbelliferone compositions and methods of using same to treat respiratory diseases or disorders |
| CN114425050A (zh) * | 2022-02-09 | 2022-05-03 | 深圳大学 | 一种4-甲基伞形酮在制备抗过敏药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4451933B2 (ja) * | 1996-12-27 | 2010-04-14 | 住友化学株式会社 | 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法 |
| GB9722600D0 (en) * | 1997-10-24 | 1997-12-24 | Bio Monde Holdings Internation | Pharmaceutical compositon |
| EP1185269B1 (en) | 1999-05-24 | 2007-11-14 | Abaron Biosciences, Inc. | Glycosyltransferase inhibitors |
| JP2004517030A (ja) * | 1999-05-24 | 2004-06-10 | アバロン バイオサイエンシーズ， インコーポレイテッド | グリコシルトランスフェラーゼインヒビター |
| GB0205022D0 (en) * | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
| CA2486302A1 (en) | 2002-05-17 | 2003-11-27 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| WO2004082610A2 (en) * | 2003-03-14 | 2004-09-30 | Brigham And Women's Hospital, Inc. | Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders |
| US20080152640A1 (en) * | 2003-07-29 | 2008-06-26 | Peter Prehm | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer |
| AU2010315057B2 (en) | 2009-11-05 | 2015-05-14 | Sloan Kettering Institute For Cancer Research | Catenae: serosal cancer stem cells |
| CA2806058C (en) * | 2010-07-20 | 2016-09-13 | Halozyme, Inc. | Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| CN108686203A (zh) * | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| CN102846598A (zh) | 2012-08-03 | 2013-01-02 | 广州康臣药物研究有限公司 | 香豆素在制备AGEs形成抑制剂中的应用 |
-
2014
- 2014-08-12 CN CN201480053371.4A patent/CN105579578A/zh active Pending
- 2014-08-12 US US14/911,533 patent/US10285976B2/en active Active
- 2014-08-12 WO PCT/US2014/050770 patent/WO2015023691A2/en not_active Ceased
- 2014-08-12 JP JP2016534801A patent/JP2016530265A/ja not_active Withdrawn
- 2014-08-12 EP EP14836423.5A patent/EP3033416A4/en not_active Withdrawn
-
2019
- 2019-05-03 US US16/403,293 patent/US20200101042A1/en not_active Abandoned
- 2019-05-22 JP JP2019095974A patent/JP2019135262A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530265A5 (enExample) | ||
| JP2019135262A5 (enExample) | ||
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| JP2015131795A5 (enExample) | ||
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| JP2016163571A5 (enExample) | ||
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MA43404A (fr) | Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques | |
| EA201591379A1 (ru) | Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов | |
| JP2017511377A5 (enExample) | ||
| JP2016516074A5 (enExample) | ||
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| JP2015505564A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| CA3015494C (en) | Novel compositions and therapeutic methods | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
| EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
| EA202091308A1 (ru) | Модифицированный вакцинный штамм brucella для лечения бруцеллеза | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| JP2017505811A5 (enExample) | ||
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
| IL288940A (en) | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine |